comparemela.com

Latest Breaking News On - Clinical development strategic marketing - Page 1 : comparemela.com

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Lonza to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd haemalogiHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketing

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Lonza to manufacture drug substance for clinical supply of HaemaLogiX s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-ar.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketingPrnewswire haemalogix ltd haemalogi

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

/PRNewswire/ HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketingPrnewswire haemalogix ltd haemalogi

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Press release content from PR Newswire. The AP news staff was not involved in its creation.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketingPrnewswire haemalogix ltd haemalogi

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

/PRNewswire/ HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketingPrnewswire haemalogix ltd haemalogi

vimarsana © 2020. All Rights Reserved.